Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300690 | 0.81 | FFAR4 (0.38) | ADRB1FFAR4NOTUMPOLBHIF1A | |
| SCHEMBL14300692 | 0.81 | FFAR4 (0.38) | ADRB1FFAR4NOTUMPOLBHIF1A | |
| SCHEMBL1410217 | 0.77 | FFAR4 (0.37) | FFAR4DPP4NOTUMHIF1A | |
| SCHEMBL1410213 | 0.75 | ALDH1A1 (0.36) | FFAR4ALDH1A1 | |
| SCHEMBL12209936 | 0.73 | PTPN1 (0.38) | NOTUMPOLBHIF1A | |
| SCHEMBL1410260 | 0.71 | FFAR4 (0.44) | ADRB1FFAR4DPP4NOTUM | |
| SCHEMBL14300689 | 0.70 | FFAR4 (0.38) | ADRB1FFAR4NOTUMPOLBHIF1A | |
| SCHEMBL14300691 | 0.70 | FFAR4 (0.38) | ADRB1FFAR4NOTUMPOLBHIF1A | |
| SCHEMBL1410454 | 0.67 | ADRB1 (0.42) | ADRB1POLB | |
| SCHEMBL1410216 | 0.67 | FFAR4 (0.37) | FFAR4DPP4NOTUMALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | ADRB1 2484/4885FFAR4 4589/4885DPP4 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.